Tradegate
01.10.26 | 21:22
0,248 Euro
+1,64 % +0,004
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,240 | 0,242 | 02.10. | |
| 0,240 | 0,250 | 02.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | IGC Pharma, Inc.: IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026 | 280 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead... ► Artikel lesen | |
| IGC PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.08. | IGC Pharma Reaches 146-Patient Enrollment Target In Phase 2 Alzheimer's Agitation Trial | 9 | pulse2.com | ||
| 17.08. | IGC Pharma GAAP EPS of -$0.03 misses by $0.01, revenue of $0.27M beats by $0.17M | 6 | Seeking Alpha | ||
| 17.08. | IGC Pharma, Inc.: IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure | 810 | ACCESS Newswire | Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage... ► Artikel lesen | |
| 11.08. | IGC Pharma, Inc.: IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout | 634 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease... ► Artikel lesen | |
| 29.07. | IGC Pharma, Inc.: IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign | 3.282 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / July 29, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease... ► Artikel lesen | |
| 09.07. | IGC Pharma, Inc.: IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow | 428 | ACCESS Newswire | Seven presentations highlight patent-pending agentic automation, speech-based cognitive models, EHR mining, and predictive analytics designed to support Alzheimer's discovery and clinical development... ► Artikel lesen | |
| 07.07. | IGC Pharma CEO, finance chief buy $1.15M of common stock | 4 | Seeking Alpha | ||
| 07.07. | IGC Pharma, Inc.: IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company | 421 | ACCESS Newswire | Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including more than $552,362 of personal cash previously advanced to IGC POTOMAC, MD / ACCESS... ► Artikel lesen | |
| 06.07. | IGC Pharma, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 23.06. | IGC Pharma, Inc.: IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow | 990 | ACCESS Newswire | Patent-Pending Multi-Agent Architecture Targets Fragmented Biomedical Data and Expands Toward Imaging, Omics, and Broader Health-Data Applications Ahead of Planned AAIC 2026 Demonstration in London... ► Artikel lesen | |
| 11.06. | IGC Pharma, Inc.: IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis | 987 | ACCESS Newswire | Company Continuing Limited Over-Enrollment Activities to Account for Attrition and Support Robust Modified Intent-to-Treat, End-of-Treatment and Exploratory Analyses POTOMAC, MD / ACCESS Newswire /... ► Artikel lesen | |
| 09.06. | IGC Pharma, Inc.: Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts | 526 | ACCESS Newswire | POTOMAC, MD / ACCESS Newswire / June 9, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease,... ► Artikel lesen | |
| 08.06. | IGC Pharma, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.06. | IGC Pharma, Inc.: IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis | 441 | ACCESS Newswire | Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis POTOMAC, MD / ACCESS Newswire / June 2, 2026 / IGC Pharma... ► Artikel lesen | |
| 19.05. | IGC Pharma, Inc.: IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment | 706 | ACCESS Newswire | - Continued Advancement of CALMA Phase 2 Trial - POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 19.05. | IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.32M beats by $0.09M | 9 | Seeking Alpha | ||
| 15.05. | IGC Pharma, Inc.: IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference | 398 | ACCESS Newswire | Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development. POTOMAC, MD / ACCESS Newswire / May 15, 2026... ► Artikel lesen | |
| 28.04. | IGC Pharma, Inc.: IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase | 589 | ACCESS Newswire | Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion POTOMAC, MD / ACCESS Newswire / April 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC"... ► Artikel lesen | |
| 22.04. | IGC Pharma, Inc.: IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion | 497 | ACCESS Newswire | Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study POTOMAC, MD / ACCESS Newswire / April 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC)... ► Artikel lesen |
1 2 3 Weiter >>
56 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 44,940 | -1,01 % | 90 Milliarden US-Dollar bis 2030: Wie Bayer, Mesoblast und NurExone regenerative Medizin unterschiedlich entwickeln | ||
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| PFIZER | 24,735 | +0,18 % | Litfulo and tilrekimig data bolster Pfizer's immunology plans | ||
| NOVARTIS | 124,98 | -0,14 % | CH-Verlauf: Fester dank Novartis und Nestlé, Roche fallen ab | Zürich - Der Schweizer Aktienmarkt ist mit Schwung in die neue Woche gestartet und hat die Marke bei 14'000 klar zurückerobert. In der Folge konnte er indes dieses Niveau nicht ganz halten. Gestützt... ► Artikel lesen | |
| MERCK KGAA | 136,90 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead | ||
| AURORA CANNABIS | 3,518 | +0,86 % | Aurora Cannabis: Beschwerde bringt den Deal ins Wanken | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| ABBVIE | 231,00 | -0,35 % | AbbVie To Present New Dermatology Data At 2026 EADV Congress | WASHINGTON (dpa-AFX) - AbbVie (ABBV) said it will present new clinical and real-world data across its dermatology portfolio at the 2026 European Academy of Dermatology and Venereology (EADV)... ► Artikel lesen | |
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| CANOPY GROWTH | 0,780 | +0,72 % | Canopy Growth Corporation: Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany | Mr. Blöte's appointment strengthens Canopy Growth's commercial leadership as it drives growth across its European medical cannabis businessCanopy Growth Corporation ("Canopy Growth", "our", "we" or... ► Artikel lesen | |
| MERCK & CO | 128,18 | 0,00 % | AstraZeneca-Summit, Novo-Hengrui, Merck-Fierce Pharma Asia | ||
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 54,11 | -0,39 % | Dividendenbekanntmachungen (02.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACME UNITED CORPORATION US0048161048 0,16 USD 0,1423 EUR ALICO INC US0162301040 0,05 USD 0,0444 EUR ATN INTERNATIONAL INC US00215F1075 0... ► Artikel lesen |
Das Unternehmen IGC PHARMA INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,248 Euro und damit +1,64 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IGC PHARMA INC finden Sie auf Wallstreet Online.